Shots:

• ImmunoGen to receive $40M up front- ~$265M as development- regulatory & commercial milestones and is eligible to receive royalties on sales of mirvetuximab in Greater China and will retain all rights to mirvetuximab in the US & ROW
• The collaboration accelerates the development path for mirvetuximab in Greater China and expands Huadong’s oncology portfolio with innovative ADC and combines ImmunoGen’s lead clinical program with Huadong’s regional oncology expertise
• Mirvetuximab soravtansine (IMGN853) is a first-in-class ADC comprising a FRα binding antibody- cleavable linker & the maytansinoid DM4 to kill the targeted cancer cells

 ­ Ref: ImmunoGen | Image: PNGitem